查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1781969

受限胜肽藥物市場，按胜肽類型、按治療領域、按合成方法、按給藥途徑、按最終用戶、按國家和地區分類 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Constrained Peptide Drugs Market, By Peptide Type, By Therapeutic Area, By Synthesis Method, By Route of Administration, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年受限肽類藥物市場規模價值 15.6032 億美元，2025 年至 2032 年的複合年成長率為 16.20%。

受限的胜肽類藥物市場-市場動態

慢性病盛行率上升推動市場需求

慢性病盛行率的上升推動了全球限制性胜肽類藥物市場的成長。根據美國疾病管制與預防中心的數據，美國約有十分之六的成年人患有慢性病，這推動了對限制性胜肽類藥物等標靶療法的需求。此外，在肽類藥物穩定性方面的進步預計將是推動市場成長的另一個因素。然而，高昂的生產成本和監管挑戰預計將在未來幾年阻礙市場的成長。相反，腫瘤學應用的不斷擴展以及個人化治療投資的增加，為針對個別患者情況設計的胜肽類藥物提供了機會。

受限胜肽類藥物市場—關鍵洞察

根據我們的研究分析師的分析，預測期內（2025-2032 年）全球市場預計年複合成長率約為 16.20%

根據胜肽類型細分，預計環化胜肽將在 2024 年佔據最大市場佔有率

根據治療領域細分，腫瘤學是 2024 年領先的治療領域

根據合成方法細分，固相胜肽合成是 2024 年最主要的合成方法

根據給藥途徑細分，皮下注射是 2024 年最主要的給藥途徑

根據最終用戶細分，醫院是 2024 年領先的最終用戶

按地區分類，北美是 2024 年最大的收入來源

受限胜肽藥物市場-細分分析：

全球受限胜肽藥物市場根據胜肽類型、治療領域、合成方法、給藥途徑、最終用戶和地區進行細分。

根據胜肽的類型，市場分為四大類：環肽、大環肽、D肽和釘合肽。預計環肽將在預測期內佔據主要市場佔有率，這得益於其與其他類型的肽相比，穩定性更高、生物利用度更高，並且在治療領域應用更廣泛。

根據治療領域，市場分為兩類：傳染病、心血管疾病、中樞神經系統疾病、腫瘤和代謝失調。由於癌症盛行率的上升以及肽類藥物在標靶癌症治療中的有效性，預計腫瘤領域將在全球受限肽類藥物市場中佔據主要佔有率。

受限胜肽類藥物市場—地理洞察

預計在預測期內，北美地區將佔據主要的胜肽類藥物市場佔有率，這得益於其先進的醫療基礎設施、不斷增加的研發投入以及創新療法的廣泛採用。同時，由於醫療保健意識的提高、患者人數的增加以及新興經濟體對生物技術和製藥行業的投資不斷增加，預計亞太地區將以最快的速度成長。

受限胜肽類藥物市場-競爭格局：

對標靶和穩定療法的需求不斷成長，推動了受限肽類藥物的創新。各公司專注於推進肽類藥物的穩定技術和最佳化給藥方法，以提高療效和患者依從性。與研究機構建立策略夥伴關係和合作，加速了藥物開發並拓展了產品線。此外，在擴大生產能力和開拓新興市場方面的投資有助於滿足日益成長的醫療保健需求。對個人化醫療和新型胜肽類藥物劑型的重視，進一步增強了公司在不斷變化的市場格局中的競爭優勢。

最新動態：

2025 年 1 月，Bicycle Therapeutics plc 分享了澤來奈肽培維多汀與派姆單抗治療不適用順鉑的轉移性尿路上皮癌患者的 1 期聯合用藥最新結果，以及 2025 年的主要成就和戰略計劃。

目錄

第 1 章：受限胜肽藥物市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 受限制的胜肽類藥物市場片段（按肽類分類）
    • 受限制的胜肽類藥物市場片段（按治療領域）
    • 受限胜肽類藥物市場片段（依合成法）
    • 受限制的胜肽類藥物市場片段（依給藥途徑）
    • 受最終用戶限制的胜肽類藥物市場片段
    • 受限制的胜肽類藥物市場（按國家/地區）
    • 受限制的胜肽類藥物市場片段（按地區）
  • 競爭洞察

第3章：受限胜肽藥物關鍵市場趨勢

  • 肽類藥物市場促進因素受限
    • 市場促進因素的影響分析
  • 肽類藥物市場限制因素
    • 市場限制的影響分析
  • 受限的胜肽類藥物市場機會
  • 肽類藥物市場未來趨勢受限

第4章：受限胜肽類藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：受限制的胜肽類藥物市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：受限的胜肽類藥物市場格局

  • 2024年受限肽類藥物市場佔有率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：受限胜肽藥物市場－依胜肽類型

  • 概述
    • 按肽類型分類的細分市場佔有率分析
    • 環化胜肽
    • 大環肽
    • D-胜肽
    • 訂書釘胜肽

第8章：受限胜肽藥物市場-依治療領域

  • 概述
    • 按治療領域分類的細分市場佔有率分析
    • 傳染病
    • 心血管疾病
    • 中樞神經系統疾病
    • 腫瘤學
    • 代謝紊亂

第9章：受限胜肽藥物市場－依合成方法

  • 概述
    • 細分市場佔有率分析（採用綜合法）
    • 固相胜肽合成
    • 重組技術

第 10 章：受限胜肽藥物市場 - 按給藥途徑

  • 概述
    • 按治療領域分類的細分市場佔有率分析
    • 口服
    • 靜脈
    • 透皮
    • 皮下

第 11 章：受限胜肽藥物市場 - 按最終用戶

  • 概述
    • 按最終用戶細分的佔有率分析
    • 醫院
    • 研究機構
    • 製藥公司

第 12 章：受限胜肽藥物市場-按地域分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美受限制的胜肽類藥物主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模及預測（按肽類型）
    • 北美市場規模及預測（按治療領域）
    • 北美市場規模及預測（綜合法）
    • 北美市場規模及預測（按給藥途徑）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲受限制的胜肽類藥物主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（按胜肽類型）
    • 歐洲市場規模及預測（按治療領域）
    • 歐洲市場規模及預測（綜合法）
    • 歐洲市場規模及預測（依管理途徑）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區受限胜肽類藥物主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依胜肽類型）
    • 亞太地區市場規模及預測（依治療領域）
    • 亞太地區市場規模及預測（依綜合法）
    • 亞太地區市場規模及預測（依管理途徑）
    • 亞太地區市場規模及預測（依最終用戶）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲受限肽類藥物主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按肽類型）
    • 拉丁美洲市場規模及預測（按治療領域）
    • 拉丁美洲市場規模及預測（依綜合法）
    • 拉丁美洲市場規模及預測（依管理途徑）
    • LATAM 規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲受限肽類藥物主要製造商
    • 中東和非洲市場規模及預測（按國家/地區）
    • 中東和非洲市場規模及預測（按胜肽類型）
    • 中東和非洲市場規模及預測（按治療領域）
    • 中東及非洲市場規模及預測（綜合法）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 13 章：關鍵供應商分析-受限胜肽藥物產業

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • Amgen Inc.
    • Pfizer Inc.
    • Novartis AG
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.
    • Sanofi SA
    • Bicycle Therapeutics PLC
    • Bristol-Myers Squibb Company
    • Aileron Therapeutics, Inc.
    • Eli Lilly and Company
    • Aileron Therapeutics Inc.
    • Spexis AG
    • Santhera Pharmaceuticals
    • Protagonist Therapeutics Inc.
    • Union Chimique Belge SA (UCB)
    • Biosynth (Pepscan)
    • Creative Peptides
    • Pepticom Ltd.
    • Bio-Synthesis Inc.
    • PeptiDream Inc.
    • CPC Scientific Inc.
    • Chugai Pharmaceutical Co. Ltd.
    • Circle Pharma
    • Others

第 14 章：360 度分析師視角

第 15 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5366

REPORT HIGHLIGHT

Constrained peptide drugs market size was valued at US$ 1,560.32 Million in 2024, expanding at a CAGR of 16.20% from 2025 to 2032.

Constrained peptide drugs are specially designed molecules where the peptide's structure is chemically "locked" into a stable shape. This constraint improves their stability, enhances binding to specific targets, and increases resistance to degradation by enzymes in the body. These features make them highly effective in treating diseases by precisely interacting with biological molecules, offering advantages over traditional peptides such as improved potency, selectivity, and longer-lasting therapeutic effects.

Constrained Peptide Drugs Market- Market Dynamics

Increasing prevalence of chronic diseases to propel market demand

The rising prevalence of chronic diseases is driving the growth of the global constrained peptide drugs market. According to the CDC, approximately 6 in 10 adults in the U.S. have a chronic disease, driving demand for targeted therapies like constrained peptide drugs. Besides, advancements in peptide stabilization is another factor projected to boost the market growth. However, high production costs and regulatory challenges is expected to hamper the market growth in the coming years. On the contrary, expanding applications in oncology and increasing investment in personalized, providing opportunities for peptide drugs designed for individual patient profiles.

Constrained Peptide Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 16.20% over the forecast period (2025-2032)

Based on Peptide Type segmentation, cyclized peptides was predicted to show maximum market share in the year 2024

Based on Therapeutic Area segmentation, oncology was the leading Therapeutic Area in 2024

Based on Synthesis Method segmentation, solid phase peptide synthesis was the leading Synthesis Method in 2024

Based on Route of Administration segmentation, subcutaneous was the leading Route of Administration in 2024

Based on end user segmentation, Hospital was the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Constrained Peptide Drugs Market- Segmentation Analysis:

The Global Constrained Peptide Drugs Market is segmented on the basis of Peptide Type, Therapeutic Area, Synthesis Method, Route of Administration, End User, and Region.

The market is divided into four categories based on Peptide Type: cyclized peptides, macrocyclic peptides, D-peptides, and stapled peptides. The cyclized peptides segment is expected to hold the major market share during the forecast period, driven by their enhanced stability, improved bioavailability, and widespread applications in therapeutic areas compared to other peptide types.

The market is divided into two categories based on Therapeutic Area: infectious diseases, cardiovascular diseases, Cns Disorders, oncology, and metabollic disorders. The oncology segment is expected to hold the major market share in the global constrained peptide drugs market, due to increasing cancer prevalence and the effectiveness of peptide drugs in targeted cancer therapies.

Constrained Peptide Drugs Market- Geographical Insights

The North America region is expected to hold the major constrained peptide drugs market share during the forecast period, driven by advanced healthcare infrastructure, increased R&D investments, and high adoption of innovative therapies. Meanwhile, the Asia-Pacific region is projected to grow at the fastest rate due to rising healthcare awareness, expanding patient populations, and growing investments in biotechnology and pharmaceutical sectors across emerging economies.

Constrained Peptide Drugs Market- Competitive Landscape:

Rising demand for targeted and stable therapeutics drives innovation in constrained peptide drugs. Companies focus on advancing peptide stabilization technologies and enhancing delivery methods to improve efficacy and patient compliance. Strategic partnerships and collaborations with research institutes accelerate drug development and expand product pipelines. Additionally, investments in expanding manufacturing capabilities and penetrating emerging markets help capitalize on growing healthcare needs. Emphasis on personalized medicine and novel peptide formats further strengthens competitive positioning in this evolving landscape.

Recent Developments:

In January 2025, Bicycle Therapeutics plc shared updated Phase 1 combination results for zelenectide pevedotin with pembrolizumab in cisplatin-ineligible metastatic urothelial cancer patients, along with key accomplishments and strategic plans for 2025.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Sanofi S.A.
  • Bicycle Therapeutics PLC
  • Bristol-Myers Squibb Company
  • Aileron Therapeutics, Inc.
  • Eli Lilly and Company
  • Aileron Therapeutics Inc.
  • Spexis AG
  • Santhera Pharmaceuticals
  • Protagonist Therapeutics Inc.
  • Union Chimique Belge S.A. (UCB)
  • Biosynth (Pepscan)
  • Creative Peptides
  • Pepticom Ltd.
  • Bio-Synthesis Inc.
  • PeptiDream Inc.
  • CPC Scientific Inc.
  • Chugai Pharmaceutical Co. Ltd.
  • Circle Pharma
  • Others

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY PEPTIDE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Cyclized Peptides
  • Macrocyclic Peptides
  • D-Peptides
  • Stapled Peptides

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Infectious Diseases
  • Cardiovascular Diseases
  • Cns Disorders
  • Oncology
  • Metabollic Disorders

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY SYNTHESIS METHOD- MARKET ANALYSIS, 2019 - 2032

  • Solid Phase Peptide Synthesis
  • Recombinant Technology

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous
  • Transdermal
  • Subcutaneous

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Research Institutes
  • Pharmaceutical Companies

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Constrained Peptide Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Constrained Peptide Drugs Market Snippet by Peptide Type
    • 2.1.2. Constrained Peptide Drugs Market Snippet by Therapeutic Area
    • 2.1.3. Constrained Peptide Drugs Market Snippet by Synthesis Method
    • 2.1.4. Constrained Peptide Drugs Market Snippet by Route of Administration
    • 2.1.5. Constrained Peptide Drugs Market Snippet by End User
    • 2.1.6. Constrained Peptide Drugs Market Snippet by Country
    • 2.1.7. Constrained Peptide Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Constrained Peptide Drugs Key Market Trends

  • 3.1. Constrained Peptide Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Constrained Peptide Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Constrained Peptide Drugs Market Opportunities
  • 3.4. Constrained Peptide Drugs Market Future Trends

4. Constrained Peptide Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Constrained Peptide Drugs Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Constrained Peptide Drugs Market Landscape

  • 6.1. Constrained Peptide Drugs Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Constrained Peptide Drugs Market - By Peptide Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Peptide Type, 2024 & 2032 (%)
    • 7.1.2. Cyclized Peptides
    • 7.1.3. Macrocyclic Peptides
    • 7.1.4. D-Peptides
    • 7.1.5. Stapled Peptides

8. Constrained Peptide Drugs Market - By Therapeutic Area

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
    • 8.1.2. Infectious Diseases
    • 8.1.3. Cardiovascular Diseases
    • 8.1.4. Cns Disorders
    • 8.1.5. Oncology
    • 8.1.6. Metabollic Disorders

9. Constrained Peptide Drugs Market - By Synthesis Method

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Synthesis Method, 2024 & 2032 (%)
    • 9.1.2. Solid Phase Peptide Synthesis
    • 9.1.3. Recombinant Technology

10. Constrained Peptide Drugs Market - By Route of Administration

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
    • 10.1.2. Oral
    • 10.1.3. Intravenous
    • 10.1.4. Transdermal
    • 10.1.5. Subcutaneous

11. Constrained Peptide Drugs Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 11.1.2. Hospitals
    • 11.1.3. Research Institutes
    • 11.1.4. Pharmaceutical Companies

12. Constrained Peptide Drugs Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Constrained Peptide Drugs Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Constrained Peptide Drugs Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Constrained Peptide Drugs Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Constrained Peptide Drugs Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Constrained Peptide Drugs Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Constrained Peptide Drugs Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Amgen Inc.
    • 13.2.2. Pfizer Inc.
    • 13.2.3. Novartis AG
    • 13.2.4. Merck & Co., Inc.
    • 13.2.5. F. Hoffmann-La Roche Ltd.
    • 13.2.6. Sanofi S.A.
    • 13.2.7. Bicycle Therapeutics PLC
    • 13.2.8. Bristol-Myers Squibb Company
    • 13.2.9. Aileron Therapeutics, Inc.
    • 13.2.10. Eli Lilly and Company
    • 13.2.11. Aileron Therapeutics Inc.
    • 13.2.12. Spexis AG
    • 13.2.13. Santhera Pharmaceuticals
    • 13.2.14. Protagonist Therapeutics Inc.
    • 13.2.15. Union Chimique Belge S.A. (UCB)
    • 13.2.16. Biosynth (Pepscan)
    • 13.2.17. Creative Peptides
    • 13.2.18. Pepticom Ltd.
    • 13.2.19. Bio-Synthesis Inc.
    • 13.2.20. PeptiDream Inc.
    • 13.2.21. CPC Scientific Inc.
    • 13.2.22. Chugai Pharmaceutical Co. Ltd.
    • 13.2.23. Circle Pharma
    • 13.2.24. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us